FINWIRES · TerminalLIVE
FINWIRES

Woojin I&S KRW11.9 Billion Secures Office Construction Order from SK ecoplant

By

Woojin I&S (KRX:010400) secured an order from SK Inc. (KRX:034730) subsidiary SK ecoplant for the construction of a temporary facility and fire protection for the Phase 4 IBL FAB integrated office at the Yongin Cluster Phase One.

The contract, valued at 11.9 billion won, is valid till May 31, 2027, according to a Tuesday filing by the South Korean mechanical equipment producer and construction firm with the Korea Exchange.

Shares of Woojin I&S closed marginally higher, while those of SK Inc. added 2% at the close of Tuesday's trade.

Related Articles

Asia

Aerospace Intelligent Manufacturing Technology Obtains 53 Patent Certificates

Aerospace Intelligent Manufacturing Technology (SHE:300446) obtained 53 patent certificates from China's intellectual property management agency, according to a Tuesday disclosure to the Shenzhen bourse.Ten of them are invention patents, including a bumper paint detection device and a car bumper injection mold.The company also obtained 35 utility model patents, including a gantry mechanism for injection mold hydraulic cylinders, and eight are design patents.

$SHE:300446
Asia

Tong Ren Tang Chinese Medicine Gets Registered to Sell Liver Pacifying Capsules in Hong Kong

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) obtained a registration certificate allowing it to sell its Antelope Horn Powder Capsules in Hong Kong, according to a Tuesday bourse filing.The Certificate of Registration of Proprietary Chinese Medicine was obtained from the Chinese Medicine Council of Hong Kong.The capsules are mainly indicated for pacifying the liver and extinguishing wind, clearing the liver, improving vision, dissipating blood, and removing toxins, the medicine maker said.

$HKG:3613
Asia

Aarti Pharmalabs' Fiscal Q4 Consolidated Profit Slumps

Aarti Pharmalabs (NSE:AARTIPHARM, BOM:543748) reported a decline in its attributable consolidated profit to 611.2 million Indian rupees in the fiscal fourth quarter ended March 31 from 883.4 million rupees a year earlier, according to a Tuesday filing on the Indian bourses.Earnings per share contracted to 6.74 rupees from 9.74 rupees in the same quarter last year.Net revenue from operations rose to 5.83 billion rupees from 5.64 billion rupees a year ago.The company recommended a final dividend of 2 rupees per share for the fiscal year ended March 31.

$BOM:543748$NSE:AARTIPHARM